2015 American Transplant Congress
The Relationship Between Age and Morbidity During the First Year Following Renal Transplantation in Patients Receiving Alemtuzumab Induction
Vanderbilt University Medical Center, Nashville.
BackgroundThe elderly (age ≥ 65) represent the largest growing patient population being listed for renal transplant. Immunosuppression in elderly patients presents a unique challenge, with…2015 American Transplant Congress
Alemtuzumab Induction Is Associated With a Lower Risk of Early Rehospitalization After Kidney Transplant
Early rehospitalizations within the first 30 days (R-30D) are common after kidney transplant. R-30D are costly and associated with an increased risk of graft failure…2015 American Transplant Congress
Induction Therapy Improves 15-Year Graft Survival in Kidney Transplant Recipients With Acute Rejection
Transplant Institute, Henry Ford Hospital, Detroit, MI.
Background: Graft(GS) and patient survival(PS) has been shown to be superior in patients without delayed graft function (DGF) or acute rejection(AR). Induction therapy(IT) is frequently…2015 American Transplant Congress
Long Term Outcomes With Alemtuzumab Induction Therapy for Deceased and Living Renal Transplant Recipients. A Single Center Experience
Ochsner Clinic Foundation, New Orleans, LA.
Background:Antibody induction therapy has been used for induction in up to 80% kidney transplant recipients according to United Network for Organ Sharing. It has been…2015 American Transplant Congress
Deceased Donor HLA Antibody Incompatible Renal Transplantation Without Antibody Removal: High Incidence of Acute Rejection Reduced By T-Cell Depleting Induction Therapy
Aims: Screening for HLA-specific antibodies (Ab) is routine for patients on kidney transplant waiting lists, and HLA antigens to which a patient has detectable Ab…2015 American Transplant Congress
Propensity Score-Weighted Analysis of Induction Therapies in Live Donor Kidney Transplantation in Modern Immunosuppression Era
1Medicine, UTSW, Dallas, TX; 2Clinical Sciences, UTSW, Dallas, TX; 3Surgery, UTSW, Dallas, TX.
Background: Induction therapy with interleukin-2 receptor antagonist (IL2-RA) is recommended as a first line agent in living donor renal transplantation (LRT). However, use of IL2-RA…2015 American Transplant Congress
A Comparison of Alemtuzumab and Antithymocyte Globulin Induction in High-Risk, Non-Sensitized African American Renal Transplant Recipients
Background:Greater than 90% of all kidney transplants(KTx) today receive an induction agent. The choice of a depleting or non-depleting agent is center specific. Alemtuzumab (Alem),…2015 American Transplant Congress
Inadequate Overall Immunosuppression Is a Risk for Late Acute Rejection Despite Alemtuzumab Induction in Simultaneous Pancreas Kidney Transplant Recipients
Introduction: Simultaneous pancreas-kidney transplantation (SPK) has become the treatment of choice for patients with end-stage renal disease due to Type 1 Diabetes Mellitus. SPK is…2015 American Transplant Congress
Alemtuzumab Induction Has Been Safe in the United Kingdom and Achieves Long-Term Steroid Avoidance in More Than 80% of Low Risk Renal Transplant Recipients
Introduction: The use of alemtuzumab as an induction agent for renal transplantation is increasing in the UK. There is some evidence to suggest that this…2015 American Transplant Congress
Infections After Alemtuzumab Induction: A Non Issue?
Transplant Institute, Tulane University, New Orleans, LA.
Background: Alemtuzumab is a powerful induction agent that depletes multiple lymphocyte cell lines resulting in leukopenia and/or neutropenia with concerns over infectious complications. This study…
American Transplant Congress abstracts